We sought to investigate the prevalence and the spectrum of ECG abnormalities in such patients.\n\nWe assessed 125 patients with isolated LVA or LVD for the prevalence of ECG abnormalities and compared the findings to an age- and gender-matched control group. The 12-lead ECG patterns were evaluated according to commonly used criteria and were classified into three subgroups (distinct, mildly, and minor). Fifty-four of the 125 patients

(43.2%) had normal and 71 (56.8%) abnormal ECGs. Mean age was 66 years. Forty-nine (39.2%) were male. Distinct abnormal ECG patterns were more prevalent in patients with LVD (38.2 vs. 15.8%, P = 0.04), and apical location of the anomaly (36.6 vs. 16.6%, P = 0.02). Older age (> 66 years) GSK2118436 solubility dmso was associated with a trend for a higher prevalence of abnormal ECG pattern (33 vs. 18%, P = 0.06), whereas gender had no influence (32 vs. 16%, SNS-032 P = 0.14). This study also shows that the sensitivity, specificity, positive

predictive value and negative predictive value of a 12-lead ECG for the diagnosis of LVA or LVD are low.\n\nThis large single-centre study suggests that the prevalence of abnormal ECG patterns in patients with isolated LVA or LVD is as high as 56.8%. However, ECG is not specific and sensitive to be used as a screening tool in such patients.”
“Myelofibrosis (MF) is characterized by splenomegaly,

anemia and a debilitating symptom burden (e.g., fatigue, night sweats, pruritus, bone and muscle pain, undesired weight loss). Moreover, these symptoms impair activities of daily living and quality of life. Until recently, there have been no approved therapies for MF, and management of MF has been predominantly palliative. Dysregulated JAK-STAT signaling is associated with the pathologic MF disease state. A novel class of therapies, the JAK inhibitors, offers the potential to abrogate this pathologic signaling pathway. In clinical trials of patients with intermediate- and high-risk MF, JAK inhibitors have demonstrated efficacy in reducing splenomegaly and MF-associated symptoms. Evidence from ruxolitinib BI 2536 trials also suggests that JAK inhibitors may improve survival outcomes.”
“In this work a simple and efficient finite element model is used for the damping optimization of multilayer sandwich plates, with a viscoelastic core sandwiched between elastic layers, including piezoelectric layers. The elastic layers are modeled using the classical plate theory and the core is modeled using Reddy’s third-order shear deformation theory. The finite element formulation is obtained by assembly of N “elements” through the thickness, using specific assumptions on the displacement continuity at the interfaces between layers.